Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADMIRE-HF: 123I-mIBG Scintigraphy in Heart Failure
NCT00126438Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Jul 2005
- Primary completion
- Jul 2008
- Countries
- 1
01
Overview
Phase 3, open-label trial of Iobenguane I-123 in heart failure (HF), sponsored by GE HealthCare. Primary endpoint: Relationship Between Adverse Cardiac Events and 123I-mIBG Uptake (H/M Ratio) at 24 months. Started Jul 2005; status: completed.
02
Drugs
Iobenguane I-123
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00126438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126438.